Cobenfy Capsule, Coated Pellets
Product Images NDC 0003-0050
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cobenfy (NDC 0003-0050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Cobenfy 02)
Change From Baseline Panss (Cobenfy 03)
50 mg/20 mg Bottle Labels (Cobenfy 04)
100 mg/20 mg Bottle Labels (Cobenfy 05)
125 mg/30 mg Capsule Bottle Label (Cobenfy 06)
This is a medication label for COBENFY capsules containing 125 mg of xanomeline and 30 mg of trospium chloride. The storage instructions advise keeping it between 20°C to 25°C (68°F to 77°F). It is important to keep this medicine out of reach of children. The recommended dosage is one capsule twice daily. This medication is distributed by Bristol-Myers Squibb Company and is a product of Karuna Therapeutics, Inc.*
Starter Pack Carton (Cobenfy 07)
This text provides crucial information regarding the drug COBENFY, a medication marketed by Bristol-Myers Squibb Company. The drug is available in two formulations - 50 mg/20 mg and 100 mg/20 mg capsules - containing xanomeline and trospium chloride as active ingredients. The recommended dosage is one capsule twice daily. The storage conditions require keeping the drug at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The package includes a Starter Pack with 56 capsules for a 28-day dosing regimen. Remember to keep all drugs out of the reach of children.*
Sample Titration Pack (Image 01)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.